ORIC — Oric Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1796280 ·
Last close
$12.03
Market Cap
$1.25B
52W High
$14.68
52W Low
$7.23
ADV30
1,465,254
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -45,296,000 | -41,492,000 | 404,685,000 | 37,483,000 | 23,429,000 |
| Mar 2026 | 0 | — | -39,619,000 | -35,767,000 | 436,762,000 | 56,396,000 | 21,205,000 |
| Dec 2025 | 0 | — | -34,551,000 | -30,505,000 | 408,890,000 | 45,669,000 | 24,528,000 |
| Sep 2025 | 0 | — | -36,671,000 | -32,587,000 | 431,192,000 | 49,668,000 | 24,273,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-111,638,000
Investing CF
$-99,662,000
Financing CF
$172,919,000
CapEx
$-620,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-769,501,000
Inventory
—
Receivables
—
ST Investments
$227,278,000
EBIT TTM
$-156,137,000
Pretax Income TTM
$-140,351,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -143,004,000 | -129,468,000 | 408,890,000 | 24,528,000 | 384,362,000 | -110,970,000 |
| Dec 2024 | 0 | -142,895,000 | -127,847,000 | 274,142,000 | 31,020,000 | 243,122,000 | -112,662,000 |
| Dec 2023 | 0 | -110,780,000 | -100,697,000 | 252,007,000 | 27,919,000 | 224,088,000 | -85,688,000 |
| Dec 2022 | 0 | -86,767,000 | -89,122,000 | 247,178,000 | 24,827,000 | 222,351,000 | -75,143,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-135,214,000
OpCashFlow TTM
—
Assets (Latest)
$436,762,000
Forward EPS
$-1.61
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | $1.27B | $20.56 | — |
| KLRA | Kailera Therapeutics, Inc. | $1.30B | $10.00 | — |
| TYRA | Tyra Biosciences, Inc. | $1.19B | $19.97 | — |
| KARD | Kardigan, Inc. | $1.33B | $14.20 | — |
| NBTX | Nanobiotix S.A. | $1.16B | $22.90 | — |
News headlines (Yahoo Finance, 1h cache)
Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?
2026-10-08 17:12 · Yahoo
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
2026-10-05 20:01 · Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:30 · Yahoo
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-02 20:05 · Yahoo
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?
2026-08-07 20:15 · Yahoo
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
2026-08-03 20:05 · Yahoo
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
2026-05-17 13:23 · Yahoo
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
2026-04-06 09:08 · Yahoo
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Researc
2026-04-17 20:05 · Yahoo
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
2026-09-15 09:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.